| | |
Page
|
| |||
FREQUENTLY USED TERMS
|
| | | | | | |
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
| | | | | | |
| | | | 1 | | | |
| | | | 7 | | | |
| | | | 9 | | | |
| | | | 14 | | | |
| | | | 21 | | | |
| | | | 25 | | | |
| | | | 32 | | | |
| | | | 35 | | | |
| | | | 36 | | | |
| | | | 40 | | | |
| | | | F-1 | | |
| | |
As of December 31, 2021
|
| |||||||||
| | |
Actual
|
| |
Pro
Forma |
| ||||||
Cash and cash equivalents
|
| | | $ | 23,236 | | | | | $ | 116,218 | | |
Restricted cash and short-term deposits
|
| | | | 8,698 | | | | | | 8,698 | | |
Warrants to convertible preferred shares
|
| | | | 18,623 | | | | | | — | | |
Warrant liability
|
| | | | — | | | | | | 10,137 | | |
Ordinary shares, no par value; 72,423,360 shares authorized; 40,528,913 issued and outstanding, actual; 275,000,000 shares authorized; 67,703,409 issued and outstanding, pro forma
|
| | | | — | | | | | | — | | |
Additional paid-in capital
|
| | | | 18,063 | | | | | | 178,080 | | |
Accumulated (deficit)
|
| | | | (52,840) | | | | | | (58,319) | | |
Total shareholders’ equity (deficiency)
|
| | | | (34,777) | | | | | | 119,761 | | |
Total capitalization
|
| | | $ | (34,777) | | | | | $ | 119,761 | | |
| | |
Purchase
Price |
| |
Shares
Issued |
| ||||||
HCCC public stockholders and Sponsor shares(1)
|
| | | $ | 10.00 | | | | | | 3,184,843 | | |
| | |
Shares
|
| |
%
|
| ||||||
Total Alpha Tau | | | | | | | | | | | | | |
Current Alpha Tau ordinary shareholders
|
| | | | 55,185,560 | | | | | | 81.6% | | |
HCCC Sponsor and other holders of founder shares(1)
|
| | | | 2,030,625 | | | | | | 3.0 | | |
HCCC public stockholders(1)
|
| | | | 1,154,218 | | | | | | 1.7 | | |
PIPE Investment
|
| | | | 9,251,006 | | | | | | 13.7 | | |
Total Alpha Tau Ordinary Shares Outstanding at Closing
|
| | |
|
67,621,409
|
| | | | | 100% | | |
| | |
As of
December 31, 2021 |
| |
Reflecting Actual Redemptions upon
Closing of the Business Combination on March 7, 2022 |
| ||||||||||||||||||||||||
| | |
Alpha Tau
Medical Ltd. (Historical) |
| |
Healthcare
Capital Corp. (Historical) |
| |
Transaction
Accounting Adjustments |
| | | | | | | |
Pro Forma
Combined |
| ||||||||||||
Assets | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
CURRENT ASSETS | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 23,236 | | | | | $ | 557 | | | | | $ | 275,016 | | | | |
|
3A
|
| | | | $ | 116,218 | | |
| | | | | | | | | | | | | | | | | 92,510 | | | | |
|
3C
|
| | | | | | | |
| | | | | | | | | | | | | | | | | (9,513) | | | | |
|
3F
|
| | | | | | | |
| | | | | | | | | | | | | | | | | (2,130) | | | | |
|
3I
|
| | | | | | | |
| | | | | | | | | | | | | | | | | (263,458) | | | | |
|
3B
|
| | | | | | | |
Restricted cash
|
| | | | 618 | | | | | | — | | | | | | | | | | | | | | | | | | 618 | | |
Short-term deposits
|
| | | | 8,080 | | | | | | — | | | | | | | | | | | | | | | | | | 8,080 | | |
Prepaid expenses and other receivables
|
| | | | 707 | | | | | | — | | | | | | | | | | | | | | | | | | 707 | | |
Total current assets
|
| | |
|
32,641
|
| | | |
|
557
|
| | | |
|
92,425
|
| | | | | | | | | |
|
125,623
|
| |
Long-term assets:
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Long term prepaid expenses
|
| | | | 2,028 | | | | | | — | | | | | | | | | | | | | | | | | | 2,028 | | |
Property and equipment, net
|
| | | | 7,546 | | | | | | — | | | | | | | | | | | | | | | | | | 7,546 | | |
Marketable securities held in Trust Account
|
| | | | | | | | | | 275,016 | | | | | | (275,016) | | | | |
|
3A
|
| | | | | — | | |
Total long-term assets
|
| | | | 9,574 | | | | | | 275,016 | | | | | | (275,016) | | | | | | | | | | | | 9,574 | | |
Total assets
|
| | | $ | 42,215 | | | | | $ | 275,573 | | | | | $ | (182,591) | | | | | | | | | | | $ | 135,197 | | |
LIABILITIES, CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS’ DEFICIENCY
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
CURRENT LIABILITIES: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Trade payables
|
| | | $ | 1,203 | | | | | $ | — | | | | | | | | | | | | | | | | | $ | 1,203 | | |
Other payables and accrued expenses
|
| | | | 3,202 | | | | | | — | | | | | | | | | | | | | | | | | | 3,202 | | |
Accrued expenses
|
| | | | — | | | | | | 894 | | | | | | | | | | | | | | | | | | 894 | | |
Total current liabilities
|
| | | | 4,405 | | | | | | 894 | | | | | | | | | | | | | | | | | | 5,299 | | |
LONG-TERM LIABILITIES: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Warrants to convertible preferred shares
|
| | | | 18,623 | | | | | | — | | | | | | (18,623) | | | | |
|
3D
|
| | | | | — | | |
Deferred underwriting fee payable
|
| | | | | | | | | | 10,325 | | | | | | (10,325) | | | | |
|
3I
|
| | | | | — | | |
Warrant Liability
|
| | | | — | | | | | | 10,137 | | | | | | | | | | | | | | | | | | 10,137 | | |
Total liabilities
|
| | | | 23,028 | | | | | | 21,356 | | | | | | (28,948) | | | | | | | | | | | | 15,436 | | |
Commitments and contingencies | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Convertible preferred shares, NIS 0.00 par value per share
|
| | | | 53,964 | | | | | | — | | | | | | (53,964) | | | | |
|
3D
|
| | | |
|
—
|
| |
Class A common stock, subject to possible redemption at $10 per share
|
| | | | — | | | | | | 275,000 | | | | | | (275,000) | | | | |
|
3J
|
| | | | | — | | |
| | |
As of
December 31, 2021 |
| |
Reflecting Actual Redemptions upon
Closing of the Business Combination on March 7, 2022 |
| ||||||||||||||||||||||||
| | |
Alpha Tau
Medical Ltd. (Historical) |
| |
Healthcare
Capital Corp. (Historical) |
| |
Transaction
Accounting Adjustments |
| | | | | | | |
Pro Forma
Combined |
| ||||||||||||
Shareholders’ deficiency: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Ordinary shares, NIS 0.00 par value per share
|
| | | | — | | | | | | — | | | | | | | | | | | | | | | | | | — | | |
Class A common stock, $0.0001 par value
|
| | | | — | | | | | | — | | | | | | 1 | | | | |
|
3G
|
| | | | | — | | |
| | | | | | | | | | | | | | | | | (1) | | | | |
|
3E
|
| | | | | | | |
Class B common stock, $0.0001 par value
|
| | | | — | | | | | | 1 | | | | | | (1) | | | | |
|
3G
|
| | | | | — | | |
Additional paid-in capital
|
| | | | 18,063 | | | | | | — | | | | | | 275,000 | | | | |
|
3J
|
| | | | | 178,080 | | |
| | | | | | | | | | | | | | | | | 92,510 | | | | |
|
3C
|
| | | | | | | |
| | | | | | | | | | | | | | | | | 53,964 | | | | |
|
3D
|
| | | | | | | |
| | | | | | | | | | | | | | | | | 18,623 | | | | |
|
3D
|
| | | | | | | |
| | | | | | | | | | | | | | | | | (24,777) | | | | |
|
3E
|
| | | | | | | |
| | | | | | | | | | | | | | | | | (2,779) | | | | |
|
3F
|
| | | | | | | |
| | | | | | | | | | | | | | | | | 8,195 | | | | |
|
3I
|
| | | | | | | |
| | | | | | | | | | | | | | | | | 2,739 | | | | |
|
3H
|
| | | | | | | |
| | | | | | | | | | | | | | | | | (263,458) | | | | |
|
3B
|
| | | | | | | |
Accumulated deficit
|
| | | | (52,840) | | | | | | (20,784) | | | | | | 24,778 | | | | |
|
3E
|
| | | | | (58,319) | | |
| | | | | | | | | | | | | | | | | (6,734) | | | | |
|
3F
|
| | | | | | | |
| | | | | | | | | | | | | | | | | (2,739) | | | | |
|
3H
|
| | | | | | | |
Total shareholders’ deficiency
|
| | | | (34,777) | | | | | | (20,783) | | | | | | 175,321 | | | | | | | | | | | | 119,761 | | |
Total liabilities, convertible preferred shares and shareholders’ deficiency
|
| | | $ | 42,215 | | | | | $ | 275,573 | | | | | $ | (182,591) | | | | | | | | | | | $ | 135,197 | | |
|
| | |
For the Year Ended
December 31, 2021 |
| |
Reflecting Actual Redemptions upon Closing
of the Business Combination on March 7, 2022 |
| ||||||||||||||||||||||||
| | |
Alpha Tau
Medical Ltd. (Historical) |
| |
Healthcare
Capital Corp. (Historical) |
| |
Transaction
Accounting Adjustments |
| | | | | | | |
Pro Forma
Combined |
| ||||||||||||
Research and development, net
|
| | | $ | 11,447 | | | | | | — | | | | | $ | 1,735 | | | | |
|
3CC
|
| | | | $ | 13,182 | | |
Marketing expenses
|
| | | | 482 | | | | | | — | | | | | | 83 | | | | |
|
3CC
|
| | | | | 565 | | |
General and administrative
|
| | | | 1,861 | | | | | | — | | | | | | 6,734 | | | | |
|
3AA
|
| | | | | 9,516 | | |
| | | | | | | | | | | | | | | | | 921 | | | | |
|
3CC
|
| | | | | | | |
Formation and operating costs
|
| | | | — | | | | | | 1,930 | | | | | | | | | | | | | | | | | | 1,930 | | |
Total operating loss
|
| | | | 13,790 | | | | | | 1,930 | | | | | | 9,473 | | | | | | | | | | | | 25,193 | | |
Financial (income) expenses, net
|
| | | | 13,474 | | | | | | — | | | | | | | | | | | | | | | | | | 13,474 | | |
Change in fair value of warrants
|
| | | | — | | | | | | (12,193) | | | | | | | | | | | | | | | | | | (12,193) | | |
Transaction costs allocated to warrant liabilities
|
| | | | | | | | | | 851 | | | | | | | | | | | | | | | | | | 851 | | |
Fair value of warrant liability in excess of
purchase price paid for Private Place Warrants |
| | | | | | | | | | 680 | | | | | | | | | | | | | | | | | | 680 | | |
Interest earned on marketable securities held in Trust Account
|
| | | | | | | | | | (16) | | | | | | 16 | | | | |
|
3DD
|
| | | | | — | | |
Loss (income) before taxes on income
|
| | | | 27,264 | | | | | | (8,748) | | | | | | 1,294 | | | | | | | | | | | | 28,005 | | |
Tax on income
|
| | | | 7 | | | | | | — | | | | | | — | | | | |
|
3BB
|
| | | | | 7 | | |
Net loss (income)
|
| | | $ | 27,271 | | | | | $ | (8,748) | | | | | $ | 1,294 | | | | | | | | | | | $ | 28,012 | | |
Net loss per share of ordinary shares – basic and diluted
|
| | | $ | (0.67) | | | | | $ | (0.27) | | | | | | | | | | | | | | | | | $ | (0.42) | | |
Weighted average shares of ordinary shares outstanding – basic and diluted
|
| | | | 40,534,697 | | | | | | 25,993,151 | | | | | | | | | | |
|
4
|
| | | | | 66,807,020 | | |
Net loss per share – Class B – basic
|
| | | | | | | | | $ | (0.27) | | | | | | | | | | | | | | | | | | | | |
Weighted average shares outstanding – Class B – basic
|
| | | | | | | | | | 6,827,055 | | | | | | | | | | | | | | | | | | | | |
Net loss per share – Class B – diluted
|
| | | | | | | | | $ | (0.27) | | | | | | | | | | | | | | | | | | | | |
Weighted average shares outstanding – Class B – diluted
|
| | | | | | | | | | 6,875,000 | | | | | | | | | | | | | | | | | | | | |
Shareholders
|
| |
Reflecting Actual Redemptions
upon the Closing of the Business Combination |
| |||
U.S. dollars in thousands (except share and per share data) | | | | | | | |
Numerator | | | | | | | |
Net loss (in thousands)
|
| | | $ | (28,012) | | |
Denominator(1) | | | | | | | |
Former Alpha Tau ordinary shareholders and preferred shareholders
|
| | | | 54,273,883 | | |
HCCC Sponsor and other holders of founder shares(2)
|
| | | | 2,030,625 | | |
Former Sponsor shares forfeited and new shares allocated to the Alpha Tau Board and Management(3)
|
| | | | 97,288 | | |
HCCC public stockholders
|
| | | | 1,154,218 | | |
PIPE Investment | | | | | | | |
| | | | | 9,251,006 | | |
Total shares of Alpha Tau ordinary shares outstanding at closing of the Business Combination
|
| | | | 66,807,020 | | |
Net loss per share | | | | | | | |
Basic and diluted
|
| | | $ | (0.42) | | |
Name of Selling Security holders
|
| |
Number of
Ordinary Shares |
| |
Number of
Ordinary Shares Being Offered(1) |
| |
Number of
Ordinary Shares After Offering |
| |
Percentage of
Outstanding Ordinary Shares Owned After Offering |
| ||||||||||||
YOZMA EBEST GLOBAL MEDICAL FUND(2)
|
| | | | 1,650,000 | | | | | | 1,650,000 | | | | | | — | | | | | | — | | |
YOZMA KAI NEW GROWTH FUND NO. 1(3)
|
| | | | 50,000 | | | | | | 50,000 | | | | | | — | | | | | | — | | |
SJW INTERNATIONAL CO., LTD(4).
|
| | | | 200,000 | | | | | | 200,000 | | | | | | — | | | | | | — | | |
SIWON LEE(5)
|
| | | | 300,000 | | | | | | 300,000 | | | | | | — | | | | | | — | | |
HANMI HEALTHCARE, INC(6).
|
| | | | 1,000,000 | | | | | | 1,000,000 | | | | | | — | | | | | | — | | |
GRAND DECADE DEVELOPMENTS LIMITED(7)
|
| | | | 1,000,000 | | | | | | 1,000,000 | | | | | | — | | | | | | — | | |
RR INVESTMENT 2012, LP(8)
|
| | | | 263,677 | | | | | | 50,000 | | | | | | 213,677 | | | | | | * | | |
MARVIN DEN(9)
|
| | | | 25,000 | | | | | | 25,000 | | | | | | — | | | | | | — | | |
MORRY BLUMENFELD(10)
|
| | | | 199,387 | | | | | | 55,000 | | | | | | 144,387 | | | | | | * | | |
ISSACHAR KNOLL(11)
|
| | | | 276,323 | | | | | | 50,000 | | | | | | 226,323 | | | | | | * | | |
RONALD COHEN(12)
|
| | | | 1,103,300 | | | | | | 25,000 | | | | | | 1,078,300 | | | | | | 1.6% | | |
JOSEPH VENTURES ENTITIES(13)
|
| | | | 308,785 | | | | | | 127,500 | | | | | | 181,285 | | | | | | * | | |
MICHAEL AVRUCH(14)
|
| | | | 2,137,526 | | | | | | 50,000 | | | | | | 2,087,526 | | | | | | 3.0% | | |
GEORGETTE AVRUCH(15)
|
| | | | 762,178 | | | | | | 70,000 | | | | | | 692,178 | | | | | | 1.0% | | |
LINDA ADAMS(16)
|
| | | | 426,323 | | | | | | 200,000 | | | | | | 226,323 | | | | | | * | | |
RICHARD WOLFE(17)
|
| | | | 172,362 | | | | | | 60,000 | | | | | | 112,362 | | | | | | * | | |
ARIE KRAMER(18)
|
| | | | 136,148 | | | | | | 120,000 | | | | | | 16,148 | | | | | | * | | |
MEIR JAKOBSOHN(19)
|
| | | | 186,743 | | | | | | 75,000 | | | | | | 111,743 | | | | | | * | | |
ARIE JACOBSOHN(20)
|
| | | | 64,939 | | | | | | 25,000 | | | | | | 39,939 | | | | | | * | | |
MEDISON VENTURES LTD.(21)
|
| | | | 2,992,847 | | | | | | 200,000 | | | | | | 2,722,847 | | | | | | 4.0% | | |
FIELDCREST HOLDINGS LLC(22)
|
| | | | 50,000 | | | | | | 50,000 | | | | | | — | | | | | | — | | |
RINA MAZOZ(23)
|
| | | | 10,526 | | | | | | 6,000 | | | | | | 4,526 | | | | | | * | | |
GILA ASRAF(24)
|
| | | | 6,000 | | | | | | 6,000 | | | | | | — | | | | | | — | | |
OURCROWD ENTITIES(25)
|
| | | | 2,963,523 | | | | | | 299,999 | | | | | | 2,663,524 | | | | | | 3.9% | | |
THOMAS SCHMIDEK(26)
|
| | | | 543,234 | | | | | | 100,000 | | | | | | 443,234 | | | | | | * | | |
OHAD SHAKED(27)
|
| | | | 261,212 | | | | | | 225,000 | | | | | | 36,212 | | | | | | * | | |
HANNA ANNIE BATTASH(28)
|
| | | | 2,000 | | | | | | 2,000 | | | | | | — | | | | | | — | | |
SHMUEL RUBINSTEIN(29)
|
| | | | 24,195 | | | | | | 4,000 | | | | | | 20,195 | | | | | | * | | |
ALAN PATRICOF(30)
|
| | | | 236,485 | | | | | | 25,000 | | | | | | 211,485 | | | | | | * | | |
EDMUND SHAMSI(31)
|
| | | | 1,931,220 | | | | | | 160,000 | | | | | | 1,771,220 | | | | | | 2.6% | | |
HELENE SHAMSI(32)
|
| | | | 170,176 | | | | | | 140,000 | | | | | | 30,176 | | | | | | * | | |
KAEYO INVESTMENTS LTD.(33)
|
| | | | 7,500 | | | | | | 7,500 | | | | | | — | | | | | | — | | |
451WE ALPHA2 LLC(34)
|
| | | | 1,127,049 | | | | | | 500,000 | | | | | | 627,049 | | | | | | * | | |
MARAV MAZON KOL LTD.(35)
|
| | | | 500,000 | | | | | | 500,000 | | | | | | — | | | | | | — | | |
TZALIR PHARMA LTD.(36)
|
| | | | 8,000 | | | | | | 8,000 | | | | | | — | | | | | | — | | |
AVNER GOLDENBERG(37)
|
| | | | 795,783 | | | | | | 40,000 | | | | | | 755,783 | | | | | | 1.1% | | |
ROY GOLDENBERG(38)
|
| | | | 5,000 | | | | | | 5,000 | | | | | | — | | | | | | — | | |
KAMAREA LTD(39)
|
| | | | 5,000 | | | | | | 5,000 | | | | | | — | | | | | | — | | |
ARON TENDLER(40)
|
| | | | 479,161 | | | | | | 50,000 | | | | | | 429,161 | | | | | | * | | |
LIOR OPHIR(41)
|
| | | | 21,867 | | | | | | 1,672 | | | | | | 20,195 | | | | | | * | | |
Name of Selling Security holders
|
| |
Number of
Ordinary Shares |
| |
Number of
Ordinary Shares Being Offered(1) |
| |
Number of
Ordinary Shares After Offering |
| |
Percentage of
Outstanding Ordinary Shares Owned After Offering |
| ||||||||||||
DANIEL LAVINE(42)
|
| | | | 64,515 | | | | | | 12,121 | | | | | | 52,394 | | | | | | * | | |
STUART MINTZ(43)
|
| | | | 16,981 | | | | | | 5,000 | | | | | | 11,981 | | | | | | * | | |
CSINTALAN SANDOR(44)
|
| | | | 52,438 | | | | | | 6,000 | | | | | | 46,438 | | | | | | * | | |
DAN SPINER(45)
|
| | | | 28,018 | | | | | | 5,236 | | | | | | 22,782 | | | | | | * | | |
MAOZ LEV(46)
|
| | | | 138,109 | | | | | | 3,200 | | | | | | 134,909 | | | | | | * | | |
URI SALOMON(47)
|
| | | | 95,732 | | | | | | 1,000 | | | | | | 94,732 | | | | | | * | | |
DAVID GROVAS(48)
|
| | | | 7,284 | | | | | | 5,625 | | | | | | 1,659 | | | | | | * | | |
ORI GROVAS(49)
|
| | | | 5,723 | | | | | | 4,063 | | | | | | 1,660 | | | | | | * | | |
ADAM SOKOL(50)
|
| | | | 69,671 | | | | | | 13,090 | | | | | | 56,581 | | | | | | * | | |
DONGWOOK KO(51)
|
| | | | 40,000 | | | | | | 40,000 | | | | | | — | | | | | | — | | |
MIN SOO KIM(52)
|
| | | | 50,000 | | | | | | 50,000 | | | | | | — | | | | | | — | | |
JAE SANG YOO(53)
|
| | | | 50,000 | | | | | | 50,000 | | | | | | — | | | | | | — | | |
H. PIO CO., LTD.(54)
|
| | | | 512,000 | | | | | | 512,000 | | | | | | — | | | | | | — | | |
RU KA LUKE KANG(55)
|
| | | | 30,000 | | | | | | 30,000 | | | | | | — | | | | | | — | | |
DANIEL MARTIN CO., LTD.(56)
|
| | | | 100,000 | | | | | | 100,000 | | | | | | — | | | | | | — | | |
ABBA M. KRIEGER(57)
|
| | | | 10,000 | | | | | | 10,000 | | | | | | — | | | | | | — | | |
ESTER PORAT(58)
|
| | | | 426,344 | | | | | | 30,000 | | | | | | 396,344 | | | | | | * | | |
CHAN SOO KIM(59)
|
| | | | 40,000 | | | | | | 40,000 | | | | | | — | | | | | | — | | |
MINSU YU(60)
|
| | | | 10,000 | | | | | | 10,000 | | | | | | — | | | | | | — | | |
BIG MOVE VENTURES, CO. LTD.(61)
|
| | | | 100,000 | | | | | | 100,000 | | | | | | — | | | | | | — | | |
KIM JONG SEON(62)
|
| | | | 156,000 | | | | | | 156,000 | | | | | | — | | | | | | — | | |
NURIFLEX, CO., LTD.(63)
|
| | | | 200,000 | | | | | | 200,000 | | | | | | — | | | | | | — | | |
NURIVISTA, CO., LTD.(63)
|
| | | | 200,000 | | | | | | 200,000 | | | | | | — | | | | | | — | | |
NURIBILL, CO., LTD.(63)
|
| | | | 200,000 | | | | | | 200,000 | | | | | | — | | | | | | — | | |
Expenses
|
| |
Amount
|
| |||
SEC registration fee
|
| | | $ | 25,990 | | |
FINRA filing fee
|
| | | | * | | |
Transfer agent’s fee
|
| | | | * | | |
Printing and engraving expenses
|
| | | | * | | |
Legal fees and expenses
|
| | | | * | | |
Accounting fees and expenses
|
| | | | * | | |
Miscellaneous costs
|
| | | | * | | |
Total
|
| | | $ | * | | |
| Audited Financial Statements of Alpha Tau Medical Ltd. | | | | | | | |
| | | | | F-2 | | | |
| | | | | F-3 | | | |
| | | | | F-4 | | | |
| | | | | F-5 | | | |
| | | | | F-6 | | | |
| | | | | F-7 | | | |
| Audited Financial Statements of Healthcare Capital Corp. | | | | | | | |
| | | | | F-30 | | | |
| | | | | F-31 | | | |
| | | | | F-32 | | | |
| | | | | F-33 | | | |
| | | | | F-34 | | | |
| | | | | F-35 | | |
| | | | | | | | |
December 31,
|
| |||||||||
| | |
Note
|
| |
2020
|
| |
2021
|
| |||||||||
ASSETS
|
| | | | | | | | | | | | | | | | | | |
CURRENT ASSETS: | | | | | | | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | | | | | | | $ | 15,598 | | | | | $ | 23,236 | | |
Restricted cash
|
| | | | | | | | | | 576 | | | | | | 618 | | |
Short-term deposits
|
| | | | | | | | | | 30,417 | | | | | | 8,080 | | |
Prepaid expenses and other receivables
|
| | | | 3 | | | | | | 864 | | | | | | 707 | | |
Total current assets
|
| | | | | | | | | | 47,455 | | | | | | 32,641 | | |
Long-term assets: | | | | | | | | | | | | | | | | | | | |
Long term prepaid expenses
|
| | | | | | | | | | 139 | | | | | | 2,028 | | |
Property and equipment, net
|
| | | | 4 | | | | | | 5,395 | | | | | | 7,546 | | |
Total long-term assets
|
| | | | | | | | | | 5,534 | | | | | | 9,574 | | |
Total assets
|
| | | | | | | | | $ | 52,989 | | | | | $ | 42,215 | | |
LIABILITIES, CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS’ DEFICIENCY
|
| | | | | | | | | | | | | | | | | | |
CURRENT LIABILITIES: | | | | | | | | | | | | | | | | | | | |
Trade payables
|
| | | | | | | | | $ | 964 | | | | | $ | 1,203 | | |
Other payables and accrued expenses
|
| | | | 5 | | | | | | 1,124 | | | | | | 3,202 | | |
Total current liabilities
|
| | | | | | | | | | 2,088 | | | | | | 4,405 | | |
LONG-TERM LIABILITIES: | | | | | | | | | | | | | | | | | | | |
Warrants to convertible preferred shares
|
| | | | 7 | | | | | | 5,366 | | | | | | 18,623 | | |
Total liabilities
|
| | | | | | | | | | 7,454 | | | | | | 23,028 | | |
Commitments and Contingencies
|
| | | | 6 | | | | | | | | | | | | | | |
Convertible Preferred shares of no-par value per share – Authorized: 25,348,176 shares as of December 31, 2020 and 2021; Issued and outstanding: 13,739,186 shares as of December 31, 2020 and 2021;(*)
|
| | | | 9 | | | | | | 53,964 | | | | | | 53,964 | | |
Shareholders’ deficiency: | | | | | | | | | | | | | | | | | | | |
Ordinary shares of no-par value per share — Authorized: 72,423,360 shares as
of December 31, 2020 and 2021; Issued and outstanding: 40,433,578 and 40,528,913 shares as of December 31, 2020 and 2021, respectively;(*) |
| |
10
|
| | | | — | | | | | | — | | | |||
Additional paid-in capital
|
| | | | | | | | | | 17,140 | | | | | | 18,063 | | |
Accumulated deficit
|
| | | | | | | | | | (25,569) | | | | | | (52,840) | | |
Total shareholders’ deficiency
|
| | | | | | | | | | (8,429) | | | | | | (34,777) | | |
Total liabilities, convertible preferred shares and shareholders’ deficiency
|
| | | | | | | | | $ | 52,989 | | | | | $ | 42,215 | | |
| | | | | |
Year ended December 31,
|
| |||||||||||||||
| | |
Note
|
| |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Research and development, net
|
| | | | | | $ | 6,636 | | | | | $ | 7,544 | | | | | $ | 11,447 | | |
Marketing expenses
|
| | | | | | | 397 | | | | | | 288 | | | | | | 482 | | |
General and administrative
|
| | | | | | | 977 | | | | | | 1,412 | | | | | | 1,861 | | |
Total operating loss
|
| | | | | | | 8,010 | | | | | | 9,244 | | | | | | 13,790 | | |
Financial (income) expenses, net
|
| |
11
|
| | | | 308 | | | | | | (520) | | | | | | 13,474 | | |
Loss before taxes on income
|
| | | | | | | 8,318 | | | | | | 8,724 | | | | | | 27,264 | | |
Tax on income
|
| | | | | | | 146 | | | | | | 158 | | | | | | 7 | | |
Net loss
|
| | | | | | $ | 8,464 | | | | | $ | 8,882 | | | | | $ | 27,271 | | |
Less: net loss attributable to noncontrolling interests
|
| | | | | | $ | 97 | | | | | $ | — | | | | | $ | — | | |
Net loss attributable to Alpha Tau Medical Ltd.
|
| | | | | | $ | 8,367 | | | | | $ | 8,882 | | | | | $ | 27,271 | | |
Net loss per share attributable to ordinary shareholders,
basic and diluted |
| | | | | | | (0.25) | | | | | | (0.22) | | | | | | (0.67) | | |
Weighted-average shares used in computing net loss per
share attributable to ordinary shareholders, basic and diluted (*) |
| | | | | | | 33,815,448 | | | | | | 40,274,935 | | | | | | 40,534,697 | | |
| | |
Convertible
Preferred Shares |
| | | | |
Additional
paid-in capital |
| |
Accumulated
deficit |
| |
Nom
controlling interest |
| |
Total
Deficit |
| ||||||||||||||||||||||||||||||
|
Ordinary
Shares |
| |||||||||||||||||||||||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||
Balances as of January 1, 2019(*)
|
| | | | 7,229,885 | | | | | $ | 25,238 | | | | | | 33,185,538 | | | | | $ | — | | | | | $ | 9,330 | | | | | $ | (8,320) | | | | | $ | 851 | | | | | $ | 1,861 | | |
Share-based compensation
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 546 | | | | | | — | | | | | | — | | | | | | 546 | | |
Issuance of ordinary shares and warrants to ordinary shares
|
| | | | — | | | | | | — | | | | | | 1,302,132 | | | | | | — | | | | | | 5,250 | | | | | | — | | | | | | — | | | | | | 5,250 | | |
Exercise of warrants to ordinary shares
|
| | | | — | | | | | | — | | | | | | 5,316,493 | | | | | | — | | | | | | 1,560 | | | | | | — | | | | | | — | | | | | | 1,560 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (8,367) | | | | | | (97) | | | | | | (8,464) | | |
Acquisition of non-controlling interests
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (192) | | | | | | — | | | | | | (754) | | | | | | (946) | | |
Balances as of January 1, 2020(*)
|
| | | | 7,229,885 | | | | | | 25,238 | | | | | | 39,804,163 | | | | | | — | | | | | | 16,494 | | | | | | (16,687) | | | | | | — | | | | | | (193) | | |
Exercise of Warrants to ordinary shares
|
| | | | — | | | | | | — | | | | | | 624,445 | | | | | | — | | | | | | 30 | | | | | | — | | | | | | — | | | | | | 30 | | |
Issuance of ordinary shares upon exercise of share options
|
| | | | — | | | | | | — | | | | | | 4,970 | | | | | | — | | | | | | 20 | | | | | | — | | | | | | — | | | | | | 20 | | |
Share-based compensation
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 596 | | | | | | — | | | | | | — | | | | | | 596 | | |
Issuance of series B Preferred shares, net
(**)
|
| | | | 6,509,301 | | | | | | 28,726 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (8,882) | | | | | | — | | | | | | (8,882) | | |
Balances as of December 31, 2020(*)
|
| | | | 13,739,186 | | | | | | 53,964 | | | | | | 40,433,578 | | | | | | — | | | | | | 17,140 | | | | | | (25,569) | | | | | | — | | | | | | (8,429) | | |
Exercise of Warrants to ordinary shares
|
| | | | — | | | | | | — | | | | | | 9,053 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Issuance of ordinary shares upon exercise of share options
|
| | | | — | | | | | | — | | | | | | 86,282 | | | | | | — | | | | | | 111 | | | | | | — | | | | | | — | | | | | | 111 | | |
Share-based compensation
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 812 | | | | | | — | | | | | | — | | | | | | 812 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (27,271) | | | | | | — | | | | | | (27,271) | | |
Balances as of December 31, 2021(*)
|
| | | | 13,739,186 | | | | | $ | 53,964 | | | | | | 40,528,913 | | | | | $ | — | | | | | $ | 18,063 | | | | | $ | (52,840) | | | | | $ | — | | | | | $ | (34,777) | | |
| | |
Year ended December 31,
|
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Cash flows from operating activities: | | | | | | | | | | | | | | | | | | | |
Net loss
|
| | | $ | (8,464) | | | | | $ | (8,882) | | | | | $ | (27,271) | | |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | | | | | | | | | | | | |
Depreciation
|
| | | | 66 | | | | | | 86 | | | | | | 776 | | |
Share-based compensation
|
| | | | 546 | | | | | | 596 | | | | | | 812 | | |
(Increase) decrease in prepaid expenses and other receivables
|
| | | | (509) | | | | | | 283 | | | | | | 157 | | |
Increase in long term prepaid expenses
|
| | | | (16) | | | | | | (123) | | | | | | (1,889) | | |
Change in the fair value of warrants to convertible preferred shares
|
| | | | 994 | | | | | | 203 | | | | | | 13,257 | | |
Non-cash financial (income) expenses, net
|
| | | | 12 | | | | | | (153) | | | | | | 29 | | |
Increase in trade payables
|
| | | | 148 | | | | | | 114 | | | | | | 239 | | |
Increase in other payables and accrued expenses
|
| | | | 313 | | | | | | 625 | | | | | | 2,078 | | |
Net cash used in operating activities
|
| | | | (6,910) | | | | | | (7,251) | | | | | | (11,812) | | |
Cash flows from investing activities: | | | | | | | | | | | | | | | | | | | |
Investment in short-term deposits
|
| | | | (54,270) | | | | | | (70,200) | | | | | | (8,082) | | |
Redemption of short-term deposits
|
| | | | 45,400 | | | | | | 66,150 | | | | | | 30,282 | | |
Purchase of property and equipment
|
| | | | (1,293) | | | | | | (3,767) | | | | | | (2,927) | | |
Net cash (used in) provided by investing activities
|
| | | | (10,163) | | | | | | (7,817) | | | | | | 19,273 | | |
Cash flows from financing activities: | | | | | | | | | | | | | | | | | | | |
Proceeds from issuance of ordinary shares and warrants
|
| | | | 5,250 | | | | | | — | | | | | | — | | |
Proceeds from issuance of series B Preferred shares, net
|
| | | | — | | | | | | 28,726 | | | | | | — | | |
Proceeds from exercise of warrants
|
| | | | 1,019 | | | | | | 571 | | | | | | — | | |
Proceeds from exercise of options
|
| | | | — | | | | | | 20 | | | | | | 111 | | |
Acquisition of non-controlling interest
|
| | | | (946) | | | | | | — | | | | | | — | | |
Net cash provided by financing activities
|
| | | | 5,323 | | | | | | 29,317 | | | | | | 111 | | |
Effect of exchange rate changes on cash, cash equivalents and restricted cash
|
| | | | (18) | | | | | | 84 | | | | | | 108 | | |
(Decrease) increase in cash and cash equivalents and restricted cash
|
| | | | (11,768) | | | | | | 14,333 | | | | | | 7,680 | | |
Cash, cash equivalents and restricted cash at the beginning of the year
|
| | | | 13,609 | | | | | | 1,841 | | | | | | 16,174 | | |
Cash, cash equivalents and restricted cash at the end of the year
|
| | | $ | 1,841 | | | | | $ | 16,174 | | | | | $ | 23,854 | | |
Non-cash transactions: | | | | | | | | | | | | | | | | | | | |
Receivables from exercise of warrants to ordinary shares
|
| | | $ | 541 | | | | | $ | — | | | | | $ | — | | |
Supplemental disclosures of cash flow information: | | | | | | | | | | | | | | | | | | | |
Income tax payments
|
| | | $ | — | | | | | $ | 218 | | | | | $ | 103 | | |
Interest received
|
| | | $ | 780 | | | | | $ | 541 | | | | | $ | 351 | | |
| | |
December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
Cash and cash equivalents, as reported on the balance sheets
|
| | | $ | 15,598 | | | | | $ | 23,236 | | |
Restricted cash, as reported on the balance sheets
|
| | | | 576 | | | | | | 618 | | |
Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows
|
| | | $ | 16,174 | | | | | $ | 23,854 | | |
| | |
%
|
|
Computers and software
|
| |
33
|
|
Laboratory equipment
|
| |
10 – 15
|
|
Furniture and office equipment
|
| |
7 – 15
|
|
Car
|
| |
20
|
|
Manufacturing equipment
|
| |
10
|
|
Leasehold improvements
|
| |
Over the shorter of the
term of the lease or its useful life |
|
| | |
Year Ended December 31,
|
| ||||||
| | |
2019
|
| |
2020
|
| |
2021
|
|
Expected term (years)
|
| |
5.4 – 7.1
|
| |
2.0 – 6.2
|
| |
5.0 – 6.3
|
|
Expected volatility
|
| |
85.3% – 88.6%
|
| |
90.8% – 102.1%
|
| |
85.5% – 89.2%
|
|
Risk-free interest rate
|
| |
1.9% – 2.6%
|
| |
0.1% – 0.5%
|
| |
0.8% – 1.4%
|
|
Expected dividend yield
|
| |
0%
|
| |
0%
|
| |
0%
|
|
| | |
December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
Government authorities
|
| | | $ | 472 | | | | | $ | 458 | | |
Prepaid expenses
|
| | | | 387 | | | | | | 227 | | |
Other receivables
|
| | | | 5 | | | | | | 22 | | |
| | | | $ | 864 | | | | | $ | 707 | | |
| | |
December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
Cost: | | | | | | | | | | | | | |
Manufacturing equipment(*)
|
| | | $ | 5,058 | | | | | $ | 7,238 | | |
Computers and software
|
| | | | 128 | | | | | | 394 | | |
Laboratory equipment
|
| | | | 251 | | | | | | 719 | | |
Furniture and office equipment
|
| | | | 37 | | | | | | 50 | | |
Cars
|
| | | | 57 | | | | | | 57 | | |
Leasehold improvements
|
| | | | 34 | | | | | | — | | |
| | | | | 5,565 | | | | | | 8,458 | | |
Accumulated depreciation
|
| | | | 170 | | | | | | 912 | | |
Depreciated cost
|
| | | $ | 5,395 | | | | | $ | 7,546 | | |
| | |
December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
Employees and payroll accruals
|
| | | $ | 525 | | | | | $ | 788 | | |
Accrued expenses
|
| | | | 551 | | | | | | 2,366 | | |
Related parties
|
| | | | 48 | | | | | | 48 | | |
| | | | $ | 1,124 | | | | | $ | 3,202 | | |
As of December 31, 2021
|
| | | | | | |
2022
|
| | | $ | 775 | | |
2023
|
| | | | 722 | | |
2024
|
| | | | 724 | | |
2025
|
| | | | 590 | | |
2026
|
| | | | 605 | | |
Thereafter
|
| | | | 4,948 | | |
| | | | $ | 8,364 | | |
| | |
December 31,
|
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Expected term
|
| | | | 3 | | | | | | 2.25 | | | | | | 1.25 | | |
Expected dividend yield
|
| | | | 0% | | | | | | 0% | | | | | | 0% | | |
Expected volatility
|
| | | | 78.11% | | | | | | 96.83% | | | | | | 83.00% | | |
Risk-free interest rate
|
| | | | 1.91% | | | | | | 0.42% | | | | | | 0.75% | | |
| | |
2020
|
| |
2021
|
| ||||||
Beginning of year
|
| | | $ | 5,163 | | | | | $ | 5,366 | | |
Change in fair value
|
| | | | 203 | | | | | | 13,257 | | |
End of year
|
| | | $ | 5,366 | | | | | $ | 18,623 | | |
| | |
Year ended December 31,
|
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Domestic (Israel)
|
| | | $ | 8,898 | | | | | $ | 9,322 | | | | | $ | 27,089 | | |
Foreign
|
| | | | (580) | | | | | | (598) | | | | | | 175 | | |
Total
|
| | | $ | 8,318 | | | | | $ | 8,724 | | | | | $ | 27,264 | | |
| | |
Year ended December 31,
|
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Current: | | | | | | | | | | | | | | | | | | | |
Israel
|
| | | $ | — | | | | | $ | — | | | | | $ | — | | |
Foreign
|
| | | | 146 | | | | | | 158 | | | | | | 7 | | |
Total current income tax expense
|
| | | | 146 | | | | | | 158 | | | | | | 7 | | |
Deferred: | | | | | | | | | | | | | | | | | | | |
Domestic (Israel)
|
| | | | — | | | | | | — | | | | | | — | | |
Foreign
|
| | | | — | | | | | | — | | | | | | — | | |
Total deferred income tax expense
|
| | | | — | | | | | | — | | | | | | — | | |
Income tax expense
|
| | | $ | 146 | | | | | $ | 158 | | | | | $ | 7 | | |
| | |
December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
Reserves and allowances
|
| | | $ | 22 | | | | | $ | 18 | | |
R&D expenses
|
| | | | 482 | | | | | | 399 | | |
Intangible assets
|
| | | | 44 | | | | | | 31 | | |
Stock-based compensation
|
| | | | 134 | | | | | | 33 | | |
Loss carryforward
|
| | | | 1,551 | | | | | | 3,322 | | |
Deferred tax assets before valuation allowance
|
| | | | 2,233 | | | | | | 3,803 | | |
Less – valuation allowance
|
| | | | (2,233) | | | | | | (3,803) | | |
Net deferred tax assets
|
| | | $ | — | | | | | $ | — | | |
| | |
December 31, 2020
|
| |
December 31, 2021
|
| | | | | | | | | | | | | ||||||||||||||||||
| | |
Authorized
|
| |
Issued and
outstanding |
| |
Authorized
|
| |
Issued and
outstanding |
| |
Carrying
amount |
| |
Liquidation
preference |
| ||||||||||||||||||
| | |
Number of shares
|
| | | | | | | | | | | | | |||||||||||||||||||||
Series A Convertible Preferred shares
of no-par value(*) |
| | | | 16,295,256 | | | | | | 7,229,885 | | | | | | 16,295,256 | | | | | | 7,229,885 | | | | | $ | 25,238 | | | | | $ | 36,437 | | |
Series B Convertible Preferred shares
of no- par value(*) |
| | | | 9,052,920 | | | | | | 6,509,301 | | | | | | 9,052,920 | | | | | | 6,509,301 | | | | | | 28,726 | | | | | | 28,761 | | |
Total
|
| | | | 25,348,176 | | | | | | 13,739,186 | | | | | | 25,348,176 | | | | | | 13,739,186 | | | | | $ | 53,964 | | | | | $ | 65,198 | | |
| | |
December 31, 2020
|
| |
December 31, 2021
|
| ||||||||||||||||||
| | |
Authorized
|
| |
Issued and
outstanding |
| |
Authorized
|
| |
Issued and
outstanding |
| ||||||||||||
| | |
Number of shares
|
| |||||||||||||||||||||
Ordinary shares of no-par value(*)
|
| | | | 72,423,360 | | | | | | 40,433,578 | | | | | | 72,423,360 | | | | | | 40,528,913 | | |
Employees
|
| |
Year ended December 31, 2021
|
| |||||||||||||||||||||
|
Number
of options |
| |
Weighted
average exercise price |
| |
Aggregate
intrinsic value |
| |
Weighted
average remaining contractual life (years) |
| ||||||||||||||
Outstanding at beginning of year
|
| | | | 4,062,408 | | | | | $ | 3.40 | | | | | $ | 944,820 | | | | | | 7.78 | | |
Granted
|
| | | | 1,321,211 | | | | | $ | 9.81 | | | | | | | | | | | | | | |
Exercised
|
| | | | (4,809) | | | | | $ | 4.42 | | | | | | | | | | | | | | |
Forfeited and cancelled
|
| | | | (53,238) | | | | | $ | 5.16 | | | | | | | | | | | | | | |
Outstanding at end of year
|
| | | | 5,325,572 | | | | | $ | 4.97 | | | | | $ | 17,854,046 | | | | | | 7.42 | | |
Exercisable options
|
| | | | 3,233,657 | | | | | $ | 3.23 | | | | | $ | 14,184,527 | | | | | | 6.56 | | |
Service Providers
|
| |
Year ended December 31, 2021
|
| |||||||||||||||||||||
|
Number
of options |
| |
Weighted
average exercise price |
| |
Aggregate
intrinsic value |
| |
Weighted
average remaining contractual life (years) |
| ||||||||||||||
Outstanding at beginning of year
|
| | | | 662,006 | | | | | $ | 2.79 | | | | | $ | 313,200 | | | | | | 6.91 | | |
Granted
|
| | | | 140,667 | | | | | $ | 9.79 | | | | | | | | | | | | | | |
Exercised
|
| | | | (81,476) | | | | | $ | 1.10 | | | | | | | | | | | | | | |
Forfeited and cancelled
|
| | | | — | | | | | | | | | | | | | | | | | | | | |
Outstanding at end of year
|
| | | | 721,197 | | | | | $ | 4.34 | | | | | $ | 2,695,213 | | | | | | 6.61 | | |
Exercisable options
|
| | | | 580,745 | | | | | $ | 3.05 | | | | | $ | 2,649,873 | | | | | | 5.89 | | |
| | |
Number of RSU
|
| |||
Outstanding at beginning of year
|
| | | | — | | |
Granted
|
| | | | 1,036,850 | | |
Forfeited and cancelled
|
| | | | (5,600) | | |
Outstanding on December 31, 2021
|
| | | | 1,031,250 | | |
| | |
Year ended
December 31, |
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Research and development
|
| | | $ | 380 | | | | | $ | 372 | | | | | $ | 654 | | |
Marketing expenses
|
| | | | 18 | | | | | | 20 | | | | | | 7 | | |
General and administrative
|
| | | | 148 | | | | | | 204 | | | | | | 151 | | |
Total share-based compensation expense
|
| | | $ | 546 | | | | | $ | 596 | | | | | $ | 812 | | |
| | |
Year ended December 31,
|
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Financial expenses: | | | | | | | | | | | | | | | | | | | |
Foreign currency transaction loss, net
|
| | | $ | 79 | | | | | $ | — | | | | | $ | 412 | | |
Remeasurement of warrants
|
| | | | 994 | | | | | | 203 | | | | | | 13,257 | | |
Others
|
| | | | 11 | | | | | | 14 | | | | | | 16 | | |
Total financial expenses
|
| | | | 1,084 | | | | | | 217 | | | | | | 13,685 | | |
| | |
Year ended December 31,
|
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Financial income: | | | | | | | | | | | | | | | | | | | |
Foreign currency transaction profit, net
|
| | | | — | | | | | | 101 | | | | | | — | | |
Interest from deposits
|
| | | | 776 | | | | | | 613 | | | | | | 211 | | |
Others
|
| | | | — | | | | | | 23 | | | | | | — | | |
Total financial income
|
| | | | 776 | | | | | | 737 | | | | | | 211 | | |
Financial expenses (income), net
|
| | | $ | 308 | | | | | $ | (520) | | | | | $ | 13,474 | | |
|
| | |
Year ended December 31,
|
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Numerator: | | | | | | | | | | | | | | | | | | | |
Net loss attributable to Ordinary shareholders
|
| | | $ | (8,367) | | | | | $ | (8,882) | | | | | $ | (27,271) | | |
Denominator: | | | | | | | | | | | | | | | | | | | |
Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted
|
| | | | 33,815,448 | | | | | | 40,274,935 | | | | | | 40,534,697 | | |
Net loss per share attributable to ordinary shareholders, basic and diluted
|
| | | | (0.25) | | | | | | (0.22) | | | | | | (0.67) | | |
| | |
Year ended December 31,
|
| |||||||||||||||
| | |
2019
|
| |
2020
|
| |
2021
|
| |||||||||
Convertible preferred shares
|
| | | | 7,229,885 | | | | | | 13,739,186 | | | | | | 13,739,186 | | |
Outstanding share options
|
| | | | 4,371,668 | | | | | | 4,724,414 | | | | | | 6,046,769 | | |
RSU
|
| | | | — | | | | | | — | | | | | | 1,031,250 | | |
Warrant to Preferred A shares
|
| | | | 3,614,960 | | | | | | 3,880,777 | | | | | | 3,880,777 | | |
Warrants
|
| | | | 8,436,578 | | | | | | 651,067 | | | | | | 651,067 | | |
| | | | | 23,653,091 | | | | | | 22,995,444 | | | | | | 25,349,049 | | |
| | |
December 31,
|
| |||||||||
| | |
2020
|
| |
2021
|
| ||||||
Israel
|
| | | $ | 3,540 | | | | | $ | 5,842 | | |
United States
|
| | | | 1,855 | | | | | | 1,699 | | |
Japan
|
| | | | — | | | | | | 5 | | |
Total property and equipment, net
|
| | | $ | 5,395 | | | | | $ | 7,546 | | |
| | | | ||
| Financial Statements: | | | | |
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | |
| | |
December 31,
2021 |
| |
December 31,
2020 |
| ||||||
ASSETS | | | | | | | | | | | | | |
Current assets | | | | | | | | | | | | | |
Cash
|
| | | $ | 556,494 | | | | | $ | — | | |
Total Current Assets
|
| | | | 556,494 | | | | | | — | | |
Deferred offering costs
|
| | | | — | | | | | | 165,029 | | |
Marketable securities held in Trust Account
|
| | | | 275,016,417 | | | | | | — | | |
TOTAL ASSETS
|
| | | $ | 275,572,911 | | | | | $ | 165,029 | | |
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
|
| | | | | | | | | | | | |
Current liabilities
|
| | | | | | | | | | | | |
Accrued expenses
|
| | | $ | 893,937 | | | | | $ | 1,374 | | |
Accrued offering costs
|
| | | | — | | | | | | 50,175 | | |
Due to related parties
|
| | | | — | | | | | | 89,854 | | |
Total Current Liabilities
|
| | | | 893,937 | | | | | | 141,403 | | |
Deferred underwriting fee payable
|
| | | | 10,325,000 | | | | | | — | | |
Warrant liability
|
| | | | 10,137,500 | | | | | | — | | |
Total Liabilities
|
| | | | 21,356,437 | | | | | | 141,403 | | |
Commitments and Contingencies
|
| | | | | | | | | | | | |
Class A common stock, $.0001 par value; 100,000,000 shares authorized; 27,500,000 and no shares subject to possible redemption issued and outstanding at redemption value at December 31, 2021 and 2020, respectively
|
| | | | 275,000,000 | | | | | | — | | |
Stockholders’ (Deficit) Equity
|
| | | | | | | | | | | | |
Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 6,875,000 and 6,900,000 shares issued and outstanding at December 31, 2021 and 2020, respectively
|
| | | | 687 | | | | | | 690 | | |
Additional paid-in capital
|
| | | | — | | | | | | 24,310 | | |
Accumulated deficit
|
| | | | (20,784,213) | | | | | | (1,374) | | |
Total Stockholders’ (Deficit) Equity
|
| | | | (20,783,526) | | | | | | 23,626 | | |
TOTAL LIABILITIES AND STOCKHOLDERS’
(DEFICIT) EQUITY |
| | | $ | 275,572,911 | | | | | $ | 165,029 | | |
| | |
Year Ended
December 31, 2021 |
| |
For the
Period from August 18, 2020 (Inception) through December 31, 2020 |
| ||||||
Formation and operating costs
|
| | | $ | 1,929,742 | | | | | $ | 1,374 | | |
Loss from operations
|
| | | | (1,929,742) | | | | | | (1,374) | | |
Other income (expense):
|
| | | | | | | | | | | | |
Change in fair value of warrants
|
| | | | 12,192,500 | | | | | | — | | |
Transaction costs allocated to warrant liabilities
|
| | | | (850,929) | | | | | | — | | |
Fair value of warrant liability in excess of purchase price paid for Private Placement Warrants
|
| | | | (680,000) | | | | | | — | | |
Interest earned on marketable securities held in Trust Account
|
| | | | 16,417 | | | | | | — | | |
Other income, net
|
| | | | 10,677,988 | | | | | | — | | |
Net income (loss)
|
| | | $ | 8,748,246 | | | | | $ | (1,374) | | |
Weighted average shares outstanding of Class A common stock
|
| | | | 25,993,151 | | | | | | — | | |
Basic and diluted net income per share, redeemable Class A common stock
|
| | |
$
|
0.27
|
| | | | $ | — | | |
Weighted average shares outstanding of Class B common stock
|
| | | | 6,827,055 | | | | | | 6,250,000 | | |
Basic net income (loss) per share, Class B common stock
|
| | | $ | 0.27 | | | | | $ | (0.00) | | |
Weighted average shares outstanding of Class B common stock
|
| | | | 6,875,000 | | | | | | — | | |
Diluted net income per share, Class B common stock
|
| | |
$
|
0.27
|
| | | | $ | — | | |
| | |
Class A
Common Stock |
| |
Class B
Common Stock |
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Total
Stockholders’ Equity (Deficit) |
| |||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||
Balance – August 18, 2020 (Inception)
|
| | | | — | | | | |
$
|
—
|
| | | | | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
Issuance of Class B common stock to Sponsor
|
| | |
|
—
|
| | | |
|
—
|
| | | | | 6,900,000 | | | | | | 690 | | | | | | 24,310 | | | | | | — | | | | | | 25,000 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (1,374) | | | | | | (1,374) | | |
Balance – December 31, 2020
|
| | | | — | | | | | $ | — | | | | | | 6,900,000 | | | | | $ | 690 | | | | | | 24,310 | | | | | | (1,374) | | | | | | 23,626 | | |
Remeasurement Adjustment on redeemable common stock
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (24,313) | | | | | | (29,531,085) | | | | | | (29,555,398) | | |
Forfeiture of Founder Shares
|
| | | | — | | | | | | — | | | | | | (25,000) | | | | | | (3) | | | | | | 3 | | | | | | — | | | | | | — | | |
Net income
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 8,748,246 | | | | | | 8,748,246 | | |
Balance – December 31, 2021
|
| | | | — | | | | | $ | — | | | | |
|
6,875,000
|
| | | |
$
|
687
|
| | | | $ | — | | | | |
$
|
(20,784,213)
|
| | | |
$
|
(20,783,526)
|
| |
| | |
Year Ended
December 31, 2021 |
| |
For the Period
from August 18, 2020 (Inception) through December 31, 2020 |
| ||||||
Cash Flows from Operating Activities: | | | | | | | | | | | | | |
Net income (loss)
|
| | | $ | 8,748,246 | | | | | $ | (1,374) | | |
Adjustments to reconcile net income (loss) to net cash used in operating activities:
|
| | | | | | | | | | | | |
Change in fair value of warrants
|
| | | | (12,192,500) | | | | | | — | | |
Transaction costs allocated to warrant liabilities
|
| | | | 850,929 | | | | | | — | | |
Fair Value of Warrant Liability in excess of Purchase Price
|
| | | | 680,000 | | | | | | — | | |
Interest earned on marketable securities held in Trust Account
|
| | | | (16,417) | | | | | | — | | |
Changes in operating assets and liabilities:
|
| | | | | | | | | | | | |
Accrued expenses
|
| | | | 892,563 | | | | | | 1,374 | | |
Net cash used in operating activities
|
| | |
|
(1,037,179)
|
| | | | | — | | |
Cash Flows from Investing Activities: | | | | | | | | | | | | | |
Investment of cash in Trust Account
|
| | | | (275,000,000) | | | | | | — | | |
Net cash used in investing activities
|
| | |
|
(275,000,000)
|
| | | | | — | | |
Cash Flows from Financing Activities: | | | | | | | | | | | | | |
Proceeds from sale of Units, net of underwriting discounts paid
|
| | | | 270,200,000 | | | | | | — | | |
Proceeds from sale of Private Placement Warrants
|
| | | | 6,800,000 | | | | | | — | | |
Proceeds from promissory note – related party
|
| | | | 258 | | | | | | 89,854 | | |
Repayment of promissory note – related party
|
| | | | (90,112) | | | | | | (89,854) | | |
Payments of offering costs
|
| | | | (316,473) | | | | | | — | | |
Net cash provided by financing activities
|
| | |
|
276,593,673
|
| | | | | — | | |
Net Change in Cash
|
| | |
|
556,494
|
| | | | | — | | |
Cash – Beginning
|
| | | | — | | | | | | — | | |
Cash – Ending | | | | $ | 556,494 | | | | |
$
|
—
|
| |
Non-cash investing and financing activities: | | | | | | | | | | | | | |
Offering costs included in accrued offering costs
|
| | | $ | — | | | | | $ | 50,175 | | |
Offering costs paid by Sponsor in exchange for issuance of Founder Shares
|
| | | $ | — | | | | | $ | 25,000 | | |
Remeasurement adjustment on redeemable common stock
|
| | | $ | 29,555,398 | | | | | $ | — | | |
Deferred underwriting fee payable
|
| | | $ | 10,325,000 | | | | | $ | — | | |
Initial classification of warrant liability
|
| | | $ | 22,330,000 | | | | | $ | — | | |
Forfeiture of Founder Shares
|
| | | $ | (3) | | | | | $ | — | | |
|
Gross proceeds
|
| | | $ | 275,000,000 | | |
| Less: | | | | | | | |
|
Proceeds allocated to Public Warrants
|
| | | | (14,850,000) | | |
|
Class A common stock issuance costs
|
| | | | (14,705,398) | | |
| Plus: | | | | | | | |
|
Accretion of carrying value to redemption value
|
| | | | 29,555,398 | | |
|
Class A common stock subject to possible redemption
|
| | | $ | 275,000,000 | | |
| | |
Year Ended
December 31, 2021 |
| |
For the Period from
August 18, 2020 (Inception) Through December 31, 2020 |
| ||||||||||||||||||
| | |
Class A
|
| |
Class B
|
| |
Class A
|
| |
Class B
|
| ||||||||||||
Basic net income (loss) per common stock | | | | | | | | | | | | | | | | | | | | | | | | | |
Numerator: | | | | | | | | | | | | | | | | | | | | | | | | | |
Allocation of net income (loss), as adjusted
|
| | | $ | 6,928,490 | | | | | $ | 1,819,756 | | | | | $ | — | | | | | $ | (1,374) | | |
Denominator: | | | | | | | | | | | | | | | | | | | | | | | | | |
Basic weighted average shares outstanding
|
| | | | 25,993,151 | | | | | | 6,827,055 | | | | | | — | | | | | | 6,250,000 | | |
Basic net income per common stock
|
| | | $ | 0.27 | | | | | $ | 0.27 | | | | | $ | — | | | | | $ | (0.00) | | |
| | |
Year Ended
December 31, 2021 |
| |
For the Period from
August 18, 2020 (Inception) Through December 31, 2020 |
| ||||||||||||||||||
| | |
Class A
|
| |
Class B
|
| |
Class A
|
| |
Class B
|
| ||||||||||||
Diluted net income per common stock | | | | | | | | | | | | | | | | | | | | | | | | | |
Numerator: | | | | | | | | | | | | | | | | | | | | | | | | | |
Allocation of net income, as adjusted
|
| | | $ | 6,928,490 | | | | | $ | 1,829,862 | | | | | $ | — | | | | | $ | — | | |
Denominator: | | | | | | | | | | | | | | | | | | | | | | | | | |
Diluted weighted average shares outstanding
|
| | | | 25,993,151 | | | | | | 6,875,000 | | | | | | — | | | | | | — | | |
Diluted net income per common stock
|
| | | $ | 0.27 | | | | | $ | 0.27 | | | | | $ | — | | | | | $ | — | | |
| | |
December 31,
2021 |
| |
December 31,
2020 |
| ||||||
Deferred tax assets: | | | | | | | | | | | | | |
Net operating loss carryforward
|
| | | $ | 38,737 | | | | | $ | 289 | | |
Start-up and organizational costs
|
| | | | 274,984 | | | | | | — | | |
Total deferred tax assets
|
| | | | 313,721 | | | | | | 289 | | |
Valuation Allowance
|
| | | | (313,721) | | | | | | (289) | | |
Net deferred tax assets
|
| | | $ | — | | | | | $ | — | | |
| | |
December 31,
2021 |
| |
December 31,
2020 |
| ||||||
Federal | | | | | | | | | | | | | |
Current
|
| | | $ | — | | | | | $ | — | | |
Deferred
|
| | | | (313,432) | | | | | | (289) | | |
State and Local | | | | | | | | | | | | | |
Current
|
| | | | — | | | | | | — | | |
Deferred
|
| | | | — | | | | | | — | | |
Change in valuation allowance
|
| | | | 313,432 | | | | | | 289 | | |
Income tax provision
|
| | | $ | — | | | | | $ | — | | |
| | |
December 31,
2021 |
| |
December 31,
2020 |
| ||||||
Statutory federal income tax rate
|
| | | | 21.0% | | | | | | 21.0% | | |
Change in fair value of warrants
|
| | | | (29.3)% | | | | | | 0.0% | | |
Transaction costs allocated to warrant liabilities
|
| | | | 2.0% | | | | | | 0.0% | | |
Fair value of warrant liability in excess of purchase price paid for Private Placement Warrants
|
| | | | 1.6% | | | | | | 0.0% | | |
Facilitative Merger Costs
|
| | | | 1.0% | | | | | | | | |
Valuation allowance
|
| | | | 3.6% | | | | | | (21.0)% | | |
Income tax provision
|
| | | | 0.0% | | | | | | 0.0% | | |
Description
|
| |
Level
|
| |
December 31,
2021 |
| |
December 31,
2020 |
| |||||||||
Assets: | | | | | | | | | | | | | | | | | | | |
Marketable securities held in Trust Account – U.S. Treasury Securities
Money Market Fund |
| | | | 1 | | | | | $ | 275,016,417 | | | | |
$
|
—
|
| |
Liabilities: | | | | | | | | | | | | | | | | | | | |
Warrant liability – Public Warrants
|
| | | | 1 | | | | | | 6,737,500 | | | | |
|
—
|
| |
Warrant liability – Private Placement Warrants
|
| | | | 3 | | | | | | 3,400,000 | | | | |
|
—
|
| |
Input
|
| |
January 20,
2021 (Initial Measurement) |
| |||
Risk-free interest rate
|
| | | | 0.62% | | |
Trading days per year
|
| | | | 250 | | |
Expected volatility
|
| | | | 16.4% | | |
Exercise price
|
| | | $ | 11.50 | | |
Stock Price
|
| | | $ | 9.46 | | |
Input
|
| |
December 31,
2021 |
| |||
Risk-free interest rate
|
| | | | 1.27% | | |
Trading days per year
|
| | | | 250 | | |
Expected volatility
|
| | | | 9.7% | | |
Exercise price
|
| | | $ | 11.50 | | |
Stock price
|
| | | $ | 9.82 | | |
| | |
Private
Placement Warrants |
| |
Public
Warrants |
| |
Warrant
Liabilities |
| |||||||||
Fair value as of January 1, 2021
|
| | | $ | — | | | | | $ | — | | | | | $ | — | | |
Initial measurement on January 20, 2021
|
| | | | 7,480,000 | | | | | | 14,850,000 | | | | | | 22,330,000 | | |
Change in fair value
|
| | | | (3,196,000) | | | | | | (6,187,500) | | | | | | (9,383,500) | | |
Transfer to Level 1
|
| | |
|
—
|
| | | | | (8,662,500) | | | | | | (8,662,500) | | |
Fair value as of March 31, 2021
|
| | | $ | 4,284,000 | | | | |
$
|
—
|
| | | | $ | 4,284,000 | | |
Change in fair value
|
| | | | 816,000 | | | | |
|
—
|
| | | | | 816,000 | | |
Fair value as of June 30, 2021
|
| | | | 5,100,000 | | | | |
|
—
|
| | | | | 5,100,000 | | |
Change in fair value
|
| | | | (340,000) | | | | |
|
—
|
| | | | | (340,000) | | |
Fair value as of September 30, 2021
|
| | | $ | 4,760,000 | | | | |
$
|
—
|
| | | | $ | 4,760,000 | | |
Change in fair value
|
| | | | (1,360,000) | | | | |
|
—
|
| | | | | (1,360,000) | | |
Fair value as of December 31, 2021
|
| | | $ | 3,400,000 | | | | |
$
|
—
|
| | | | $ | 3,400,000 | | |